<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Issuance of Priority Review Voucher; Rare Pediatric Disease Product</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <style>
        body { font-family: Arial, sans-serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { color: #333; }
        .metadata { color: #666; font-size: 0.9em; }
        .summary { margin-top: 20px; line-height: 1.5; }
        .source { margin-top: 20px; }
    </style>
</head>
<body>
    <h1>Issuance of Priority Review Voucher; Rare Pediatric Disease Product</h1>
    <div class="metadata">Published: 2026-02-05 12:36:04</div>
    <div class="summary">The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of priority review voucher. FDA has determined that XENPOZYME (olipudase alfa-rpcp), manufactured by Genzyme Corporation, meets the criteria for a priority review voucher.</div>
    <div class="source">Source: <a href="https://www.federalregister.gov/documents/2023/12/05/2023-26652/issuance-of-priority-review-voucher-rare-pediatric-disease-product" target="_blank" rel="noopener noreferrer">https://www.federalregister.gov/documents/2023/12/05/2023-26652/issuance-of-priority-review-voucher-rare-pediatric-disease-product</a></div>
</body>
</html>
